| Metric | This Period | Prior Year Period | YoY |
|---|---|---|---|
| Revenue / Net Sales | ¥419.0B | ¥405.4B | +3.4% |
| Operating Income / Operating Profit | ¥29.2B | ¥30.0B | -2.7% |
| Ordinary Income | ¥28.4B | ¥32.0B | -11.1% |
| Net Income / Net Profit | ¥30.2B | ¥25.1B | +20.3% |
| ROE | 6.9% | 5.8% | - |
For the fiscal year ended March 2025, revenue was ¥419.0B (YoY +¥13.6B, +3.4%), Operating Income was ¥29.2B (YoY -¥0.8B, -2.7%), Ordinary Income was ¥28.4B (YoY -¥3.6B, -11.1%), and Net Income was ¥30.2B (YoY +¥5.1B, +20.3%). Revenue increased for the third consecutive year, but at the operating level profitability was squeezed by a decline in gross margin (40.8% → 38.6%) and R&D expense burden, resulting in a decrease in operating profit. Ordinary Income fell double-digits, weighed down by an equity-method loss of ¥0.9B. Conversely, Net Income rose substantially YoY (+20.3%) due to the recognition of Special Gains of ¥20.1B, including gains on sales of investment securities. Versus the full-year forecast (Operating Income ¥30.7B, Net Income ¥20.7B), operating-level performance reached 95.1% (missed), but Net Income exceeded the forecast due to one-off gains. ROE was 6.9% and Operating Margin 7.0%, both deteriorating from the prior year; combined with worsened working capital efficiency, improving cash generation will be a focus for the next period.
[Revenue] Revenue of ¥419.0B was an increase of +3.4% YoY. The company operates in a single segment, the in vitro diagnostics / assay reagents business, where increased domestic and international demand and expanded product sales contributed. Cost of goods sold was ¥257.2B (cost ratio 61.4%), resulting in a gross margin of 38.6%, down 2.2pp from 40.8% the prior year. Increases in raw material and logistics costs and changes in product mix are deemed the primary drivers of margin pressure. SG&A was ¥132.6B (SG&A ratio 31.6%), improving by approximately 1.7pp YoY, reflecting progress in efficiency including R&D expenditure of ¥36.8B (as a percentage of sales 8.8%).
[Profitability] Operating Income of ¥29.2B (YoY -2.7%) was pressured by the decline in gross margin together with increased fixed cost burden including depreciation of ¥25.4B. Operating margin was 7.0%, down 0.4pp from 7.4% a year earlier. Ordinary Income of ¥28.4B (YoY -11.1%) was weighed down by an equity-method loss of ¥0.9B and interest expense of ¥0.3B, which were not fully offset by interest income of ¥0.2B, etc. Profit before tax was ¥48.3B, up substantially YoY (+61.6%) due to one-off Special Gains of ¥20.1B (gains on sales of investment securities ¥0.5B, gains on sales of fixed assets ¥0.1B, etc.). After deducting corporate taxes of ¥11.2B, Net Income was ¥30.2B (YoY +20.3%), delivering YoY growth at the bottom line.
[Profitability] Operating margin 7.0% (down 0.4pp from 7.4% prior year), Net Income margin 7.2% (up 1.0pp from 6.2% prior year). ROE 6.9% rose from 5.0% the prior year, though this was significantly contributed by one-off gains and sustainability should be monitored. Gross margin 38.6% declined 2.2pp from 40.8% due to higher raw material and logistics costs and product mix shifts. R&D expense ratio remained high at 8.8%, supporting medium- to long-term product competitiveness.
[Cash Quality] Operating Cash Flow (OCF) was ¥40.5B, approximately 1.4x Operating Income and 1.3x Net Income, generally healthy. OCF/EBITDA was 0.74x against EBITDA of ¥54.6B, below the benchmark of 0.9, indicating deterioration in working capital efficiency (accounts receivable aging and decline in accounts payable) which suppressed cash conversion. DSO 89 days, DIO 113 days, and CCC 133 days indicate a lengthening working capital cycle.
[Investment Efficiency] Capital expenditure was ¥57.6B, 2.27x depreciation (¥25.4B), signaling active investment to expand production capacity and update equipment. ROA (on an Ordinary Income basis) was 4.5%, down from 5.2% prior year. Total asset turnover was low at 0.67x, indicating room to improve inventory and receivables efficiency.
[Financial Soundness] Equity Ratio was 70.3% (prior year 69.9%), and Debt/Equity ratio was 12.2% (defined as corporate bonds + long-term borrowings + long-term borrowings due within one year, etc. / shareholders’ equity), indicating a very conservative balance sheet. Current Ratio 218.9% and Quick Ratio 189.2% show ample liquidity. Interest-bearing debt (corporate bonds and borrowings, etc.) totaled approximately ¥86.5B, while cash & deposits were ¥109.4B, resulting in net cash. There are corporate bonds maturing within one year of ¥30.0B, but with OCF of ¥40.5B and available liquidity, repayment capability is adequate. Interest coverage is approximately 100x (EBITDA ¥54.6B / interest expense ¥0.3B + other interest expense ¥0.3B), demonstrating strong ability to service interest.
OCF of ¥40.5B decreased 33.0% from ¥60.3B the prior year. Operating cash subtotal (before working capital changes) was ¥48.1B, and working capital changes were a net outflow, primarily due to a decrease in accounts payable of -¥10.3B (compression of trade payables), with an increase in accounts receivable of +¥3.4B also pressuring cash. Inventory decrease of +¥5.1B contributed to cash generation. After corporate tax payments of ¥7.5B, OCF/Net Income was 1.3x, generally healthy, but OCF/EBITDA of 0.74x indicates weak cash conversion. Investing cash flow was -¥34.2B, led by capex of -¥57.6B. Continued aggressive investment in tangible fixed assets (2.3x depreciation) aims at mid-term productivity improvement. Free Cash Flow (OCF + Investing CF) was ¥6.2B, a large decline YoY; coverage of total shareholder returns of ¥34.8B (dividends ¥18.0B and share buybacks ¥16.8B) by FCF was 0.18x, low, implying sustainability depends on working capital efficiency improvements and OCF expansion. Financing cash flow was -¥3.2B: while ¥30.0B of long-term borrowings were raised, repayments were -¥0.5B and dividends -¥18.0B and share buybacks -¥16.8B led to net outflow. Cash and equivalents increased from ¥76.4B at the beginning of the period to ¥79.4B at the end (+¥3.0B), maintaining on-hand liquidity.
Core recurring earnings are centered on Operating Income of ¥29.2B. Non-operating income of ¥1.6B (interest income ¥0.2B, foreign exchange gains ¥0.1B, etc.) is limited (0.4% of sales), while non-operating expenses of ¥2.4B (equity-method loss ¥0.9B, interest expense ¥0.3B, etc.) exceed that. One-off items include Special Gains of ¥20.1B (4.8% of sales), comprised of gains on sales of investment securities ¥0.5B, gains on sales of fixed assets ¥0.1B, etc. Special Losses were minor at ¥0.2B (loss on disposal of fixed assets). Ordinary Income of ¥28.4B versus Profit Before Tax of ¥48.3B represents roughly a 70% increase driven by one-off gains, indicating low sustainability. The accrual ratio ((Net Income - OCF) / Total Assets) is approximately -1.7%, low, suggesting good earnings quality from an accounting perspective. Comprehensive Income was ¥37.2B, exceeding Net Income of ¥30.2B; currency translation adjustments of -¥3.3B and actuarial gains related to retirement benefits of +¥3.1B influenced the total. The divergence between Ordinary Income and Net Income is mainly due to one-off gains of ¥20.1B, so forecasts for the next year should assume their absence.
Full-year guidance: Revenue ¥420.0B (YoY +0.2%), Operating Income ¥30.7B (YoY +5.2%), Ordinary Income ¥29.0B (YoY +2.0%), Net Income ¥20.7B (YoY -44.2%). Actuals achieved 99.7% of revenue target, 95.1% of operating income target, and 98.1% of ordinary income target (missed at the operating level), while Net Income substantially exceeded guidance at 179% due to recognition of Special Gains. The projected large decline in Net Income next year (-44.2%) assumes the absence of this one-off gain; therefore, improvement in core profits (operating and ordinary) will be the key evaluation point. Recovery of gross margin and improvement in working capital efficiency (compression of DSO and DIO) will be core KPIs next period.
Annual dividend of ¥58 per share (total dividends ¥18.0B) corresponds to a Payout Ratio of 81.8% (based on basic EPS of 112.52円), a high level. This is a large increase from the prior year dividend of ¥26 (+¥32), but considering the contribution of special gains to Net Income of ¥30.2B, dividends are high on an ordinary-income basis. The company repurchased shares totaling ¥16.8B, bringing total shareholder returns to ¥34.8B and a Total Return Ratio of approximately 115% (versus Net Income). Dividend coverage by FCF is 0.34x and total return coverage by FCF is 0.18x, both low; sustainability depends on improvements in working capital efficiency and OCF expansion. The next fiscal year dividend forecast of ¥29 per semiannual dividend (annualized ¥58) suggests continuation of the dividend level, signaling a shareholder-return focused policy. However, under FCF constraints, buybacks should be employed flexibly, and maintaining dividends will require improvement in operating cash flows.
Gross Margin Deterioration Risk: Gross margin of 38.6% declined 2.2pp from 40.8% due to higher raw material and logistics costs and product mix changes. If price pass-through is delayed, maintaining the operating margin at 7.0% will be difficult and ROE may fall. If COGS ratio remains high at 61.4%, SG&A efficiency (SG&A ratio 31.6%) may not be sufficient to offset the impact, and medium-term profitability deterioration risk could materialize.
Working Capital Efficiency Deterioration: DSO 89 days, DIO 113 days, CCC 133 days indicate a lengthening working capital cycle. Accounts receivable aging and a decline in accounts payable pressured OCF of ¥40.5B, contributing to OCF/EBITDA of 0.74x and reduced cash conversion. If inventory turnover worsens (despite a slight YoY inventory reduction, DIO rose relative to sales growth), working capital needs and interest burden may increase.
Recovery Risk on Aggressive Investments: Capex of ¥57.6B is 2.27x depreciation and at a high level, intended to improve production capacity and efficiency. In the short term, increased depreciation and fixed costs are pressuring operating profitability, contributing to a decline in ROA to 4.5% (from 5.2% prior year). Recovery of invested capital depends on mid-term revenue growth and gross margin recovery; in a deteriorating market environment, overcapacity risk could emerge. Monitoring the return on investment is essential.
Profitability & Returns
| Metric | Company | Median (IQR) | Delta |
|---|---|---|---|
| Operating Margin | 7.0% | -94.2% (-358.4%–8.6%) | +101.2pp |
| Net Income Margin | 7.2% | -101.5% (-373.7%–5.9%) | +108.7pp |
Profitability metrics substantially exceed industry medians, and as a diagnostics-focused company the firm maintains a stable profitable profile.
Growth & Capital Efficiency
| Metric | Company | Median (IQR) | Delta |
|---|---|---|---|
| Revenue Growth Rate (YoY) | 3.4% | -0.6% (-22.4%–13.3%) | +4.0pp |
Revenue growth exceeds the industry median, reflecting resilient diagnostic demand and product competitiveness.
※ Source: Company compilation
Core Earnings Improvement Scenario: Although revenue has increased for three consecutive years, gross margin decline (YoY -2.2pp) and working capital efficiency deterioration (CCC 133 days) are suppressing cash generation. Key focus for the next period will be gross margin recovery via price revisions and product mix improvement, and OCF/EBITDA improvement through compression of DSO and DIO (target above 0.9x). SG&A ratio has improved to 31.6% (1.7pp YoY), indicating room for continued operational efficiency gains.
Monetization of Large-Scale Capex: Capex of ¥57.6B (2.27x depreciation) is an aggressive investment aimed at improving production capacity and efficiency, which should contribute to mid-term fixed cost reductions and expanded supply capability. In the short term, however, higher depreciation and fixed costs are pressuring Operating Income and contributing to a decline in ROA (4.5%). Monitoring metrics for investment effectiveness include recovery in gross profit margin and improvement in total asset turnover; confirmation of these trends would signal a bottoming in ROE.
Sustainability of Shareholder Returns: Total returns of ¥34.8B (dividends ¥18.0B + share buybacks ¥16.8B) equate to 115% relative to Net Income, but FCF coverage is only 0.18x, so sustainability depends on working capital efficiency improvements and OCF expansion. Next fiscal year dividend forecast of ¥29 (annualized ¥58) indicates a continued shareholder-return focus, but under FCF constraints buybacks should be used flexibly and the priority order under such constraints (maintain dividend > buybacks) will be an observation point for the next period.
This report is an earnings analysis document automatically generated by AI based on XBRL financial statement data. It is not a recommendation to invest in any specific security. Industry benchmarks are reference information compiled by the Company based on publicly available financial statements. Investment decisions are your responsibility; consult a professional advisor as needed before making any investment decisions.
---End of Report---